Last reviewed · How we verify
Olmesartan medoxomil tablets high dose
Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure.
Olmesartan medoxomil is an angiotensin II receptor antagonist that blocks the action of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Used for Hypertension.
At a glance
| Generic name | Olmesartan medoxomil tablets high dose |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By blocking the angiotensin II receptor, olmesartan medoxomil causes vasodilation and reduces peripheral resistance, leading to decreased blood pressure. This mechanism is particularly beneficial in patients with hypertension, as it helps to reduce the risk of cardiovascular events such as heart attacks and strokes.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Nausea
Key clinical trials
- A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure (PHASE4)
- Effect of Two Doses of Olmesartan Medoxomil and Amlodipine on Vascular Markers in Hypertensive Patients With Metabolic Syndrome (PHASE3)
- Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection (PHASE3)
- Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure (PHASE2, PHASE3)
- Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension (PHASE2)
- Safety and Tolerability of Azilsartan Medoxomil Plus Chlorthalidone Compared to Olmesartan Medoxomil Plus Hydrochlorothiazide in Participants With Essential Hypertension (PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension (PHASE3)
- Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: